Advertisement

Topics

ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China

07:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
ArQule eligible to receive up to $336 million including upfront, regulatory and commercial milestone payments ArQule to host investor conference call including transaction details, AACR highlights and an update on clini...

Other Sources for this Article

ArQule, Inc.
Paolo Pucci, 781-994-0300
Chief Executive Officer
www.ArQule.com

NEXT ARTICLE

More From BioPortfolio on "ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...